Abstract
To the Editor: For patients with antimalarial-refractory cutaneous lupus erythematosus (CLE), methotrexate (MTX) and mycophenolate mofetil (MMF) are frequently used.1 Although surveys show that providers have medication preference by CLE subtype, which includes acute, subacute (SCLE), and discoid (DLE), there is a lack of evidence-based research comparing responses between these medications across subtypes.2,3 We retrospectively reviewed our institutional review board–approved prospective longitudinal CLE database.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
